Legionnaires’ disease — a lung infection caused by a group of bacteria called Legionella — caused secondary cold agglutinin disease (CAD) in a 40-year-old man, a case study reports. The case, which represents the second reported case of CAD secondary to Legionnaires’ disease, suggest doctors should consider this infection…
News
Sanofi’s experimental therapy SAR445088 effectively blocks the classic complement pathway — a part of the immune system that’s implicated in cold agglutinin disease (CAD) — and reduced red blood cell destruction in a cellular model of CAD, a study showed. SAR445088’s more targeted action may make it a…
A woman with a mixed form of autoimmune hemolytic anemia (AIHA), who was having only temporary responses to standard treatment, experienced complete disease remission after being given an interleukin-23 (IL-23) inhibitor for a separate condition, a case study shows. IL-23 inhibitor therapies are used for other inflammatory diseases, but have…
Specially designed miniaturized antibodies, or nanobodies, reduced blood cell destruction in a new mouse model of a disease similar to cold agglutinin disease (CAD), a study showed. These findings suggest that the nanobodies, designed to suppress the complement cascade by blocking the complement component 2 (C2) protein, could…
A young woman developed cold agglutinin disease (CAD) secondary to pneumonia, but responded well to red blood cell transfusions and treatment with the antibiotic doxycycline, according to a U.S. report. When CAD occurs secondary to an infection, “supportive therapy and treatment of the underlying infection is sufficient,” researchers…
A rituximab-based therapy regimen successfully treated a 16-year-old girl with primary cold agglutinin disease (CAD), according to researchers in the U.S. who say the case represents “the youngest patient reported with this diagnosis.” The case study, “An unusual case of primary cold agglutinin-associated lymphoproliferative disease…
Long-term treatment with Enjaymo (sutimlimab-jome) in people with cold agglutinin disease (CAD) results in rapid and sustained reductions in red blood cell destruction and anemia, as well as clinically-meaningful reductions in fatigue. That’s according to 2.5 years of data from the Phase 3 CARDINAL clinical trial, which tested…
A man with cold agglutinin disease (CAD) was found to have another autoimmune condition called pernicious anemia and vitamin B12 deficiency, according to researchers in the U.S. who called the case a rare instance of “three ongoing medical conditions simultaneously.” The case study, “A Case Report of Cold…
An experimental treatment called HMBD-011, designed to target self-reactive antibodies and the immune B-cells that produce them, showed efficacy in a cellular model of cold agglutinin disease (CAD), according to new preclinical findings presented at a scientific conference. “HMBD-011 is a potentially first-in-class … antibody developed for treatment for…
Researchers have developed a new patient-reported outcome questionnaire to assess symptoms and the impacts to daily life associated with cold agglutinin disease (CAD). Called the CAD-Symptoms and Impact Questionnaire (CAD-SIQ), it was developed by analyzing responses from patient interviews. Reactions to cold environments and fatigue were the most commonly…
Recent Posts
- Genetic variations in underlying lymphoma influence AIHA types
- Lessons from ‘Winnie-the-Pooh’ help me navigate life with CAD
- Cost-effective rituximab-based treatment keeps CAD at bay for years
- This year, ongoing CAD symptoms dampened my holiday cheer
- Immunochemotherapy can help control CAD but it carries safety risks
- Oral therapy iptacopan eases anemia in CAD patients: Small trial
- When living with CAD, even a short trip can be a nightmare
- Real-world study confirms long-term safety of Enjaymo for CAD
- After months of fatigue, feeling better is what I want for Christmas
- Man’s case shows bacterial lung infection can ‘provoke’ clots, CAD